Stay updated on Intratumoral SD-101 + Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the Intratumoral SD-101 + Pembrolizumab Clinical Trial page.

Latest updates to the Intratumoral SD-101 + Pembrolizumab Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedFooter now shows Revision: v3.3.2 (replacing v3.3.1). No visible changes to study content or page behavior.SummaryDifference0.0%

- Check16 days agoChange DetectedPublications section now includes a note that items are automatically filled from PubMed and may not all pertain to the study. The page revision label was updated from v3.2.0 to v3.3.1.SummaryDifference0.1%

- Check24 days agoChange DetectedThe page no longer displays the funding-lapse notice that warned updates may be delayed due to appropriations, while the core study details remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check38 days agoChange DetectedNon-substantive UI and text adjustments were observed; the core study details (title, conditions, eligibility, primary/secondary outcomes) appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check67 days agoChange DetectedAdded v3.2.0 update; removed a specific resource (Head and neck squamous cell carcinoma) and removed v3.0.2.SummaryDifference0.3%

- Check68 days agoChange DetectedUpdated version to v3.1.0 and removed the resource on head and neck squamous cell carcinoma.SummaryDifference0.3%

Stay in the know with updates to Intratumoral SD-101 + Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Intratumoral SD-101 + Pembrolizumab Clinical Trial page.